Sort
10,766 grants matching “checkpoint inhibitor”
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$253,630Miguel Angel Villalona · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Project 1 - Dioxin-like Compounds Suppress IgM Responses by Targeting CD5+ (Innate-like) B cells, which can Serve as a Biomarker of Susceptibility to Environmental AHR Ligands
$253,536Norbert E Kaminski · Michigan State University · P42 · FY2022 · ES
Administrative Core
$253,500Peter Karl Sorger · Harvard Medical School · U54 · FY2021 · CA
Imaging and theranostics to detect and promote an immune reactive tumor microenvironment
$253,399Zaver M Bhujwalla · Ut Southwestern Medical Center · P41 · FY2025 · EB
Project 4
$253,399Eva Hernando · New York University School Of Medicine · P50 · FY2023 · CA
Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers
$253,224Matthias Stephan · Fred Hutchinson Cancer Research Center · R01 · FY2021 · CA
Targeting interplay between KLF4 and PRMT5 in carcinogenesis
$253,214Yong Wan · Northwestern University At Chicago · R01 · FY2020 · CA
Project 4: Immunovirotherapy
$253,206Richard G Vile · Mayo Clinic Rochester · P50 · FY2022 · CA
Project 1 - Dioxin-like Compounds Suppress IgM Responses by Targeting CD5+ (Innate-like) B cells, which can Serve as a Biomarker of Susceptibility to Environmental AHR Ligands
$253,173Norbert E Kaminski · Michigan State University · P42 · FY2023 · ES
BRIT 1: Roles in Immortalization, Checkpoints and Cancer
$252,809Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
BRIT 1: Roles in Immortalization, Checkpoints and Cancer
$252,809Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
BRIT 1: Roles in Immortalization, Checkpoints and Cancer
$252,809Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
$252,801Anita Borton Hjelmeland · Cleveland Clinic Lerner Com-Cwru · R01 · FY2011 · CA
A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
$252,801Anita Borton Hjelmeland · Cleveland Clinic Lerner Com-Cwru · R01 · FY2012 · CA
Novel oncolytic virotherapy for brain tumors
$252,708Hiroaki Wakimoto · Massachusetts General Hospital · R21 · FY2018 · NS
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$252,589Farrokh Dehdashti · Washington University · R01 · FY2024 · CA
Core 3: Mouse GBM models and Imaging Core
$252,569E. Antonio Chiocca · Brigham And Women'S Hospital · P01 · FY2021 · CA
Project 2: Microenvironment Modification and Anti-PD1 Immunotherapy of Lymphoma
$252,478George J Weiner · University Of Iowa · P50 · FY2020 · CA
Targeted Therapy for Endometrial Cancer
$252,448Kimberly K Leslie · University Of Iowa · R01 · FY2015 · CA
Targeted Therapy for Endometrial Cancer
$252,448Kimberly K Leslie · University Of Iowa · R01 · FY2016 · CA
Targeted Therapy for Endometrial Cancer
$252,448Kimberly K Leslie · University Of Iowa · R01 · FY2017 · CA
Targeted Therapy for Endometrial Cancer
$252,448Kimberly K Leslie · University Of Iowa · R01 · FY2013 · CA
Administrative Core
$252,426Peter Karl Sorger · Harvard Medical School · U54 · FY2021 · CA
Project 2: Microenvironment Modification and Anti-PD1 Immunotherapy of Lymphoma
$252,394George J Weiner · University Of Iowa · P50 · FY2017 · CA
SPORE: Targeted Therapies for Glioma - Diversity Supplement
$252,388Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2022 · CA